Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-α in an experimental murine model of colitis

Cytokine

Volumn 44, Issue 1, 2008, Pages 49-56

  Lee, Jienny ^a   Kim, Myung Sunny ^b   Kim, Eun Young ^a   Park, Hae Jung ^a   Chang, Chi Young ^a   Park, Ki Soo ^a   Jung, Da Yeon ^a   Kwon, Choon Hyuck ^a   Joh, Jae Won ^a   Kim, Sung Joo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea Food Research Institute   (South Korea)

Author keywords

B cells; MD 1; MMF; NF B; TNF

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD45RB ANTIGEN; GAMMA INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BODY WEIGHT; CELL STRAIN HT29; CROHN DISEASE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOPATHOLOGIC SKIN REACTION; INTESTINE INJURY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; WASTING SYNDROME; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, CD19; ANTIGENS, SURFACE; APOPTOSIS; B-LYMPHOCYTES; COLITIS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MYCOPHENOLIC ACID; NF-KAPPA B; T-LYMPHOCYTES, REGULATORY; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 52949117681     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.06.006     Document Type: Article

References (46)

1. Allison A.C., and Eugui E.M. Purine metabolism and immunosuppressive effects of mycophenolate mofetil. Clin Transplant 10 (1996) 77-84
2. Gonwa T.A. Mycophenolate mofetil for maintenance therapy in kidney transplantation. Clin Transplant 10 (1996) 128-130
3. Sollinger H.W. From mice to man: the preclinical history of mycophenolate mofetil. Clin Transplant 10 (1996) 85-92
4. Suthanthiran M., Morris R.E., and Strom T.B. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 28 (1996) 159-172
5. Epinette W.W., Parker C.M., Jones E.L., and Greist M.C. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 17 (1987) 962-971
6. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 11 Suppl. 8 (1993) S117-S119
7. Chanaud N.I., Vistica B., Eugui E., Nussenblatt R.B., Allison A.C., and Gery I. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 61 (1995) 429-434
8. Hao L., Chan S., and Laffery K. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci 696 (1993) 328-332
9. Jonnson C., Svensson L., and Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 116 (1999) 534-541
10. Corna D., Morigi M., Facchinetti D., Bertani T., Zoja C., and Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51 (1997) 1583-1589
11. Penny M., Boyd R., and Hall B. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 9 (1998) 2272-2282
12. Neurath M.F., Wanitschke R., Peters M., Krummenauer F., Meyer zum Buschenfelde K.H., and Schlaak J.F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44 (1999) 625-628
13. Lipsky J.J. Mycophenolate mofetil. Lancet 348 (1996) 1357-1359
14. Zeeh J.M., Zorlu I., Riley N.E., Hoffmann P., Ruwe M., Goebell H., et al. Mycophenolate mofetil reduces tissue damage and inflammation in an experimental model of colitis in rats. Scand J Gastroenterol 36 (2001) 66-70
15. Allison A.C. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant Proc 34 (2002) 2863-2866
16. Heemann U., Azuma H., Hamar P., Schmid C., Tilney N., and Philipp T. Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allograft. Transplant Immunol 4 (1996) 64-67
17. Utimura R., Fujihara C.K., Mattar A.L., Malheiros D.M., Noronha I.L., and Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63 (2003) 209-216
18. Shanahan F. IBD: immunodiagnostics, immunotherapeutics, and ectotherapeutics. Gastroenterology 120 (2001) 622-635
19. + T cells. Immunity 1 (1994) 553-562
20. hi T cells. J Exp Med 190 (1999) 1479-1492
21. Kinoshita N., Hiroi T., Ohta N., Fukuyama S., Park E.J., and Kiyono H. Autocrine IL-15 mediates intestinal epithelial cell death via the activation of neighboring intraepithelial NK cells. J Immunol 169 (2002) 6187-6192
22. De Jong Y.P., Comiskey M., Kalled S.L., Mizoguchi E., Flavell R.A., Bhan A.K., et al. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 119 (2000) 715-723
23. Olson T.S., Bamias G., Naganuma M., Rivera-Nieves J., Burcin T.L., Ross W., et al. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 114 (2004) 389-398
24. Miyake K., Shimazu R., Kondo J., Niki T., Akashi S., Ogata H., et al. MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J Immunol 161 (1998) 1348-1353
25. Sandborn W.J., and Targan S.R. Biologic therapy of IBD. Gastroenterology 122 (2002) 1592-1608
26. Van Deventer S.J. Immunotherapy of Crohn's disease. Scand J Immunol 51 (2000) 18-22
27. Hanauer S.B. Inflammatory bowel disease. N Engl J Med 334 (1996) 841-848
28. + regulatory T cells in the periphery. Gastroenterology 126 (2004) 1759-1770
29. bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 173 (2004) 3119-3130
30. Baeuerle P.A., and Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12 (1994) 141-179
31. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
32. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163 (1999) 3474-3483
33. Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P., et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94 (1993) 174-181
34. Rogler G., and Andus T. Cytokines in inflammatory bowel disease. World J Surg 22 (1998) 382-389
35. Jijon H.B., Panenka W.J., Madsen K.L., and Parsons H.G. MAP kinases contribute to IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. Am J Physiol Cell Physiol 283 (2002) 31-41
36. Akira S. Toll-like receptors and innate immunity. Adv Immunol 78 (2001) 1-56
37. Hadidi S., Chen Z., Phillips J., Yu K., and Gorczynski R.M. Antisense deoxyoligonucleotides or antibodies to murine MD-1 inhibit rejection of allogeneic and xenogeneic skin grafts in C3H mice. Transplantation 73 (2002) 1771-1779
38. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
39. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
40. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6 (2005) 571-578
41. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., and Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197 (2003) 403-411
42. Chan V.W., Mecklenbrauker I., Su I., Texido G., Leitges M., Carsetti R., et al. The molecular mechanism of B cell activation by toll-like receptor protein RP-105. J Exp Med 188 (1998) 93-101
43. Grumont R.J., Rourke I.J., O'Reilly L.A., Strasser A., Miyake K., Sha W., et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 187 (1998) 663-674
44. Seo S.K., Choi J.H., Kim Y.H., Kang W.J., Park H.Y., Suh J.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10 (2004) 1088-1094
45. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998) 1191-1193
46. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 (2003) 1206-1212